Barrett's esophagus endoscopic therapy: Difference between revisions

Jump to navigation Jump to search
Line 35: Line 35:
{{familytree | | | | | | | | | B01 | | | | | |B01=Endoscopic mucosal resection}}
{{familytree | | | | | | | | | B01 | | | | | |B01=Endoscopic mucosal resection}}
{{familytree | | |,|-|-|-|-|-|-|^|-|-|-|-|-|-|.| }}
{{familytree | | |,|-|-|-|-|-|-|^|-|-|-|-|-|-|.| }}
{{familytree | | C01 | | | | | | | | | | | |C02|C01=Low grade dysplasia|C02=High grade dysplasia|C03=T1a EAC|C04=T1bEAC}}
{{familytree | | C01 | | |C02 | | | | |C03| | | |C04|C01=Low grade dysplasia|C02=High grade dysplasia|C03=T1a EAC|C04=T1bEAC}}
{{familytree | | |!| | | | | | | | | | | | | |!| }}
{{familytree | | |!| | | | | | | | | | | | | |!| }}
{{familytree | | D01 | | | | | | | | | | | |D02|D01=D01'<br>D01''|D02=D02'<br>D02''}}
{{familytree | | D01 | | | | | | | | | | | |D02|D01=D01'<br>D01''|D02=D02'<br>D02''}}

Revision as of 18:37, 3 February 2018

Barrett's Esophagus Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Barrett's Esophagus from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Endoscopic Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Barrett's esophagus endoscopic therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Barrett's esophagus endoscopic therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Barrett's esophagus endoscopic therapy

CDC on Barrett's esophagus endoscopic therapy

Barrett's esophagus endoscopic therapy in the news

Blogs on Barrett's esophagus endoscopic therapy

Directions to Hospitals TreatingBarrett's esophagus

Risk calculators and risk factors for Barrett's esophagus endoscopic therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Manpreet Kaur, MD [2] Amresh Kumar MD [3]

Overview

Endoscopic Therapy

According to the American College of Gastroenterology, indication for the endoscopic therapy in Barrett's esophagus patients are:[1]

  • Patients with modularity in Barrett’s esophagus segment should undergo endoscopic mucosal resection of the nodular lesion(s) as the initial diagnostic and therapeutic maneuver. Histologic assessment of the endoscopic mucosal resection specimen should guide further therapy. In subjects with endoscopic mucosal resection specimens demonstrating high-grade dysplasia or intramucosal carcinoma, endoscopic ablative therapy of the remaining Barrett's esophagus should be performed.
  • In patients with endoscopic mucosal resection specimens demonstrating neoplasia at a deep margin, residual neoplasia should be assumed, and surgical, systemic, or additional endoscopic therapies should be considered.
  • Endoscopic ablative therapies should not be routinely applied to patients with nondysplastic Barrett's esophagus because of their low risk of progression to esophageal adenocarcinoma. Endoscopic eradication therapy is the procedure of choice for patients with confirmed low-grade dysplasia and confirmed high-grade dysplasia
  • In patients with T1a esophageal adenocarcinoma, endoscopic therapy is the preferred therapeutic approach, being both effective and well tolerated.
  • In patients with T1b esophageal adenocarcinoma, consultation with multidisciplinary surgical oncology team should occur before embarking on endoscopic therapy. In such patients, endoscopic therapy may be an alternative strategy to esophagectomy, especially in those with superficial (sm1) disease with a well-differentiated neoplasm lacking lymphovascular invasion, as well as those who are poor surgical candidates.
  • Routine staging of patients with nodular Barrett's esophagus with Endoscopic ultrasound or other imaging modalities before EMR has no demonstrated benefit. Given the possibility of over- and understanding, findings of these modalities should not preclude the performance of endoscopic mucosal resection to stage-early neoplasia.
  • In patients with the known T1b disease, Endoscopic ultrasound may have a role in assessing and sampling regional lymph nodes, given the increased prevalence of lymph node involvement in these patients compared with the less advanced disease.
  • In patients with dysplastic Barrett's esophagus who are to undergo endoscopic ablative therapy for the nonnodular disease, radiofrequency ablation is currently the preferred endoscopic ablative therapy.

Endoscopic therapy is classified into two types:

  • Tissue acquiring therapies are:
    • Endoscopic mucosal resection
    • Endoscopic submucosal dissection
  • Non-tissue acquiring or ablative therapies are:
    • Radiofrequency ablation
    • Photodynamic therapy
    • Cryotherapy
    • Argon plasma coagulation

Management of nodular Barrett’s esophagus: The identification of mucosal irregularities including nodularity, ulceration, or flat but irregular mucosal contour is essential to detect the areas of highest yield for neoplasia.

 
 
 
 
 
 
 
 
Endoscopically visible nodularity in Barrett’s esophagus
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endoscopic mucosal resection
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low grade dysplasia
 
 
High grade dysplasia
 
 
 
 
T1a EAC
 
 
 
T1bEAC
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D01'
D01
 
 
 
 
 
 
 
 
 
 
 
D02'
D02
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E01
 
 
 
 
 
 
 
E02
 
E03
 
 
E04
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F01
 
F02
 
 
F03





Several endoscopic therapies are available to treat severe dysplasia and cancer. During these therapies, the Barrett’s lining is destroyed or the portion of the lining that has dysplasia or cancer is cut out. The goal of the treatment is to encourage normal esophageal tissue to replace the destroyed Barrett’s lining. Endoscopic therapies are performed at specialty centers by physicians with expertise in these procedures.

References

  1. "Diagnosis and Management of Barrett's Esophagus | American College of Gastroenterology".

Template:WH Template:WS